Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $213.37 and traded as high as $225.00. Genmab A/S shares last traded at $222.21, with a volume of 278 shares changing hands.
Genmab A/S Stock Down 0.6 %
The firm has a market cap of $14.43 billion, a price-to-earnings ratio of 21.23 and a beta of 1.04. The company has a 50-day moving average price of $213.34 and a 200 day moving average price of $240.50.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Insider Trading – What You Need to Know
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- The 3 Best Blue-Chip Stocks to Buy Now
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is an Earnings Surprise?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
